Advancements in Saroglitazar Treatment for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Comprehensive Update

Abstract

Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming one among the most important prevalent the reasons for persistent liver damage on a universal scale. Saroglitazar, an emerging dual PPAR ϑ/γ agonist, has a strong PPARα impact and a minor PPARγ action, while exhibiting few adverse reactions. This drug was approved by the DGCI in the year 2013. The medicine has been shown to be useful in the therapy of non-alcoholic fatty liver disease and non-alcoholic fatty liver disease in both animal and human investigations. Here we review the research works conducted national and international level regarding usage of the saroglitazer in the management of NASH or NAFLD. Saroglitazar is a prominent drug that can be used in the management of NASH and NAFLD. It offers less side effects and most effective in limiting the cumulation of fat in the liver also it improves the biochemical parameters. However, the clinical trials in this area are less and need to conduct more trials in multiple places to give more supportive data regarding use of the saroglitazer. The review recommends further translational research in this area